Business Areas | Company Introduction | Company

Business Areas

LG Chem helps the people to lead a healthy life by strengthening its R&D competence in Life Sciences.

Life Sciences is the company's new growth engine in the mid to long term goal. The company has secured the differentiated R&D competence and has received the U.S. FDA approval for its new drugs for the first time in Korea.

The company has actively penetrated into the overseas market and has expanded the pipelines for developing new drugs with active investment in R&D. The company is doing its best to become one of the best global pharmaceutical companies.

Sales

0.53KRW trillion

2016

0.55KRW trillion

2017

0.57KRW trillion

2018

1984 Established Pharmaceuticals business division
1991 Developed World’s first4th generation Cephalosporin
2003 1st Korean NCE approved by USA FDA(Factive)
2017 Merged with LG Life Sciences

Division

Primary Care (PC)

Special Care(SC)

Aesthetic

Pipeline (New Drug)

Pipeline (New Drug) : Disease area , Code, Indication, Development stage, Research , Preclinical , clinical, Phase I , Phase II , Phase III , Remark
Disease area	Code	Indication	Development stage					Remark
Disease area	Code	Indication	Research	Preclinical	Phase I	Phase II	Phase III	Remark
Metabolic disease	LR19052	Diabetes	Research complete	Preclinical complete	Phase I complete	Phase II complete	Phase III Proceeding	Zemiglo® combination drug (Korea)
	Research complete	Preclinical complete	Phase I complete	Phase II complete	Phase III Proceeding
	LR19054	Diabetes	Research complete	Preclinical complete	Phase I Proceeding	Phase II Before proceeding	Phase III Before proceeding	Zemiglo® combination drug (China)
	Research complete	Preclinical complete	Phase I Proceeding	Phase II Before proceeding	Phase III Before proceeding
	LR19051	Diabetes	Research complete	Preclinical complete	Phase I Proceeding	Phase II Before proceeding	Phase III Before proceeding	Zemiglo® combination drug (Thailand)
	Research complete	Preclinical complete	Phase I Proceeding	Phase II Before proceeding	Phase III Before proceeding
	LR19123	Diabetes	Research complete	Preclinical Proceeding	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding
	Research complete	Preclinical Proceeding	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding
	LR19018	Diabetes	Research Proceeding	Preclinical Before proceeding	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding
Research Proceeding	Preclinical Before proceeding	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding
LR19074	Gout	Research complete	Preclinical complete	Phase I Proceeding	Phase II Before proceeding	Phase III Before proceeding
Research complete	Preclinical complete	Phase I Proceeding	Phase II Before proceeding	Phase III Before proceeding
LR19021	Obesity	Research complete	Preclinical Proceeding	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding
Research complete	Preclinical Proceeding	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding
LR19020	Obesity	Research Proceeding	Preclinical Before proceeding	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding
Research Proceeding	Preclinical Before proceeding	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding
LR19131	Metabolic disease	Research Proceeding	Preclinical Before proceeding	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding
Research Proceeding	Preclinical Before proceeding	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding
Oncology	LR19127	Oncology	Research complete	Preclinical complete	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding	Co-developed with Cue Biopharma
	Research complete	Preclinical complete	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding
	LR19125	Oncology	Research complete	Preclinical complete	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding	Co-developed with PDC Line
	Research complete	Preclinical complete	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding
	LR19129	Oncology	Research Proceeding	Preclinical Before proceeding	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding	Co-developed with Cue Biopharma
Research Proceeding	Preclinical Before proceeding	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding
LR19031	Oncology	Research Proceeding	Preclinical Before proceeding	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding
Research Proceeding	Preclinical Before proceeding	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding
LR19023	Oncology	Research Proceeding	Preclinical Before proceeding	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding
Research Proceeding	Preclinical Before proceeding	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding
Immunology	LR19055	Autoimmune disease	Research complete	Preclinical complete	Phase I complete	Phase II complete	Phase III Proceeding	Humira biosimilar
	Research complete	Preclinical complete	Phase I complete	Phase II complete	Phase III Proceeding
	LR19019	Autoimmune disease	Research complete	Preclinical complete	Phase I Proceeding	Phase II Before proceeding	Phase III Before proceeding
	Research complete	Preclinical complete	Phase I Proceeding	Phase II Before proceeding	Phase III Before proceeding
	LR19025	Degenerative disease	Research Proceeding	Preclinical Before proceeding	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding
Research Proceeding	Preclinical Before proceeding	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding
LR19024	Degenerative disease	Research Proceeding	Preclinical Before proceeding	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding
Research Proceeding	Preclinical Before proceeding	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding
LR19030	Alopecia	Research complete	Preclinical Proceeding	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding
Research complete	Preclinical Proceeding	Phase I Before proceeding	Phase II Before proceeding	Phase III Before proceeding

Medical Device and Vaccine

Pipeline (New Drug) : Disease area , Code, Indication, Development stage, Research , Preclinical , clinical, Phase I , Phase II , Phase III , Remark
Disease area	Code	Indication	Development stage					Remark
Disease area	Code	Indication	Research	Preclinical	Phase I	Phase II	Phase III	Remark
Medical Device	LR19059	Dermal filler	Research complete	Preclinical complete	Phase I complete	Phase II complete	Phase III Proceeding	China
Medical Device	Research complete	Preclinical complete	Phase I complete	Phase II complete	Phase III Proceeding
LR19059	Dermal filler	Research complete	Preclinical complete	Phase I complete	Phase II complete	Phase III Proceeding	Europe
Research complete	Preclinical complete	Phase I complete	Phase II complete	Phase III Proceeding
Vaccine	LR19113	Polio	Research complete	Preclinical complete	Phase I complete	Phase II complete	Phase III Proceeding	pneumococcus
	Research complete	Preclinical complete	Phase I complete	Phase II complete	Phase III Proceeding
	LR19122	diphtheriae, tetanus, pertussis, hepatitis B, meningitis, polio	Research complete	Preclinical complete	Phase I complete	Phase II Before proceeding	Phase III Before proceeding	pneumococcus
Research complete	Preclinical complete	Phase I complete	Phase II Before proceeding	Phase III Before proceeding
LR19115	Funded by BMGF	Research complete	Preclinical complete	Phase I complete	Phase II Proceeding	Phase III Before proceeding
Research complete	Preclinical complete	Phase I complete	Phase II Proceeding	Phase III Before proceeding

Core Products

Eutropin

Hyruan One

Zemiglo / Zemimet SR Tab

Eucept

YVOIRE

Press Releases

LG Chem exhibits the world’s top performing OLED Light Panels at Light + Building 2014 2014.04.01

LG Chem has developed Plastic Film type Flexible OLED Panels 2013.09.30

LG Chem launches 55lm/W Bendable and 80lm/W Rigid OLED light panels during second half 2013.09.30

Video

Select

Opening of a Global Innovation Center